Recurrent Transformed Chronic Lymphocytic Leukemia

12 clinical trials · Condition

Record	Firm	Date
Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies (NCT05418088)	Sumithira Vasu	2022-06-30
A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas (NCT03277729)	Fred Hutchinson Cancer Center	2017-12-05
Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter Syndrome (NCT02846623)	M.D. Anderson Cancer Center	2017-01-31

Every clearance here is in the API, with alerts when new ones post.